{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/000/SRR24149800/SRR24149800.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/099/SRR24149799/SRR24149799.fastq.gz"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["OBGYN, UCLA"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA954837"],"scientific_name":["Mus musculus"],"tag":["xref:PubMed:38360876"],"long_description":["Effective targeting of cancer-associated fibroblasts (CAFs) is hindered by the lack of specific biomarkers and a poor understanding of the mechanisms by which different populations of CAFs contribute to cancer progression. While the role of TGFβ in CAFs is well-studied, less attention has been focused on a structurally and functionally similar protein, Activin A (encoded by INHBA), which is typically associated with poor survival and advanced stage in ovarian cancer. Here, we identified INHBA(+) CAFs as key players in tumor promotion and immune evasion. In syngeneic ovarian cancer mouse models, intraperitoneal injection of the Activin A neutralizing antibody attenuated tumor progression and infiltration with the host INHBA(+) CAFs and M2 macrophages. Collectively, our study identified an INHBA(+) subset of pro-tumoral CAFs as a potential therapeutic target in ovarian cancer. Overall design: To facilitate uniform recruitment of host fibroblasts to the tumor, we used the peritoneal abrasion-facilitated C57BL/6 p53/myc/Hras model in which peritoneal wound healing facilitates the recruitment of fibroblasts into the tumor. C57BL/6 mice with peritoneal abrasion were injected i.p. with syngeneic p53/myc/Hras ovarian cancer cells (genotype: p53-/-, myc, Hras). One day after cancer cell injection, the mice received daily i.p. injections of the Activin A neutralizing antibody (n=8) or control IgG (n=7). After 10 days of treatment, mice were euthanized to assess the intraperitoneal tumor burden. Mice treated with the Activin A neutralizing antibody had smaller tumor lesions at the site of peritoneal abrasion."],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Gene expression profile at single cell level of syngeneic ovarian tumors from mice treated with inhibitory Activin-A antibody or control IgG","description":"Gene expression profile at single cell level of syngeneic ovarian tumors from mice treated with inhibitory Activin-A antibody or control IgG","dates":{"last_updated":"2025-09-24","first_public":"2023-05-02"},"accession":"PRJNA954837","cross_references":{"GEO":["GSE229529"],"taxon":["10090"],"PubMed":["38360876"]}}